Clinical trial
the Impact of Allopurinol of HRQOL in Cirrhotic Patients
Name
AqOL
Description
The study aims to evaluate the impact of allopurinol on patients' related quality of life.
Trial arms
Trial start
2022-06-15
Estimated PCD
2023-01-15
Trial end
2023-03-01
Status
Completed
Phase
Early phase I
Treatment
Allopurinol Tablet
allopurinol300mg once daily
Arms:
allopurinol
Placebo
placebo once daily
Arms:
placebo
Size
100
Primary endpoint
Chronic liver disease questionnaire
6 months
Eligibility criteria
Inclusion Criteria:
cirrhosis adult both sex
Exclusion Criteria:
* renal insufficiency
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 100, 'type': 'ACTUAL'}}
Updated at
2023-10-31
1 organization
2 products
2 indications
Organization
Tanta UniversityProduct
AllopurinolIndication
CirrhosisIndication
LiverProduct
Placebo